Two Sigma Investments, LP Protagonist Therapeutics, Inc Transaction History

Two Sigma Investments, LP

  • $42.3 Billion
  • Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 5,711 shares of PTGX stock, worth $214,619. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,711
Previous 82,637 93.09%
Holding current value
$214,619
Previous $2.86 Million 91.06%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$33.72 - $47.33 $2.59 Million - $3.64 Million
-76,926 Reduced 93.09%
5,711 $256,000
Q2 2024

Aug 14, 2024
SELL
$24.66 - $34.8 $1.85 Million - $2.61 Million
-74,957 Reduced 47.56%
82,637 $2.86 Million
Q1 2024

May 15, 2024
SELL
$21.79 - $32.15 $27,215 - $40,155
-1,249 Reduced 0.79%
157,594 $4.56 Million
Q4 2023

Feb 14, 2024
SELL
$14.05 - $23.44 $2.49 Million - $4.16 Million
-177,465 Reduced 52.77%
158,843 $3.64 Million
Q3 2023

Nov 14, 2023
SELL
$16.68 - $23.66 $669,952 - $950,303
-40,165 Reduced 10.67%
336,308 $5.61 Million
Q2 2023

Aug 14, 2023
BUY
$18.02 - $29.36 $1.24 Million - $2.02 Million
68,773 Added 22.35%
376,473 $10.4 Million
Q1 2023

May 15, 2023
SELL
$10.78 - $25.38 $1.99 Million - $4.68 Million
-184,265 Reduced 37.45%
307,700 $7.08 Million
Q4 2022

Feb 14, 2023
BUY
$7.36 - $11.17 $1.81 Million - $2.75 Million
246,260 Added 100.23%
491,965 $5.37 Million
Q3 2022

Nov 14, 2022
SELL
$7.86 - $11.71 $549,720 - $818,985
-69,939 Reduced 22.16%
245,705 $2.07 Million
Q2 2022

Aug 15, 2022
BUY
$7.06 - $25.52 $191,509 - $692,255
27,126 Added 9.4%
315,644 $2.5 Million
Q1 2022

May 16, 2022
BUY
$23.34 - $36.08 $6.08 Million - $9.4 Million
260,418 Added 926.75%
288,518 $6.83 Million
Q4 2021

Feb 14, 2022
BUY
$17.63 - $37.1 $61,705 - $129,850
3,500 Added 14.23%
28,100 $961,000
Q3 2021

Nov 15, 2021
SELL
$12.95 - $49.69 $631,662 - $2.42 Million
-48,777 Reduced 66.47%
24,600 $436,000
Q2 2021

Aug 16, 2021
SELL
$25.57 - $44.88 $259,254 - $455,038
-10,139 Reduced 12.14%
73,377 $3.29 Million
Q1 2021

May 17, 2021
SELL
$19.02 - $31.15 $1.39 Million - $2.27 Million
-72,850 Reduced 46.59%
83,516 $2.16 Million
Q4 2020

Feb 16, 2021
SELL
$18.49 - $25.13 $1.18 Million - $1.6 Million
-63,837 Reduced 28.99%
156,366 $3.15 Million
Q3 2020

Nov 16, 2020
SELL
$15.19 - $22.4 $1.06 Million - $1.56 Million
-69,775 Reduced 24.06%
220,203 $4.31 Million
Q2 2020

Aug 14, 2020
BUY
$6.19 - $18.84 $1.12 Million - $3.4 Million
180,355 Added 164.52%
289,978 $5.12 Million
Q1 2020

May 15, 2020
SELL
$5.4 - $9.22 $509,009 - $869,086
-94,261 Reduced 46.23%
109,623 $774,000
Q4 2019

Feb 14, 2020
BUY
$4.69 - $13.45 $724,431 - $2.08 Million
154,463 Added 312.55%
203,884 $1.44 Million
Q3 2019

Nov 14, 2019
SELL
$9.41 - $16.56 $684,135 - $1.2 Million
-72,703 Reduced 59.53%
49,421 $594,000
Q2 2019

Aug 14, 2019
BUY
$8.98 - $12.96 $684,698 - $988,161
76,247 Added 166.2%
122,124 $1.48 Million
Q1 2019

May 15, 2019
SELL
$6.5 - $13.77 $73,456 - $155,614
-11,301 Reduced 19.76%
45,877 $577,000
Q4 2018

Feb 14, 2019
SELL
$6.3 - $10.44 $550,248 - $911,840
-87,341 Reduced 60.44%
57,178 $385,000
Q3 2018

Nov 14, 2018
BUY
$6.82 - $11.26 $985,619 - $1.63 Million
144,519 New
144,519 $1.49 Million
Q2 2018

Aug 14, 2018
SELL
$5.99 - $9.1 $196,472 - $298,480
-32,800 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$8.46 - $23.08 $211,296 - $576,446
-24,976 Reduced 43.23%
32,800 $282,000
Q4 2017

Feb 14, 2018
BUY
$14.47 - $20.8 $836,018 - $1.2 Million
57,776
57,776 $1.2 Million

Others Institutions Holding PTGX

# of Institutions
246
Shares Held
56.8M
Call Options Held
71.7K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.84B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email